• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

    2/28/22 7:10:55 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email
    HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously
    Get the next $CRDF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    8/10/2021$25.00 → $26.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $20.00Buy
    Maxim Group
    More analyst ratings

    $CRDF
    Financials

    Live finance-specific insights

    See more
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

      2/20/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

      - Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm - - Onvansertib was well tolerated at both doses - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - - Company will hold a conference call today at 8:00 a.m. ET / 5:00 a.m. PT - SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology co

      12/10/24 6:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Cardiff Oncology with a new price target

      Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00

      9/6/24 7:59:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

      HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously

      2/28/22 7:10:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Cardiff Oncology

      William Blair initiated coverage of Cardiff Oncology with a rating of Outperform

      1/5/22 8:00:11 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,263,173 with an expected expiration date of no earlier than 2043. The claims of the patent cover the method of using onvansertib in combination with bevacizumab (bev) in any line of therapy for the treatment of metastatic colorectal cancer (mCRC) patients who have not previously been treated with bev. "The expansion of our intellectual property portfolio strategical

      4/23/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.79 per share, which is equal to the closing price of Cardiff Oncology's common stock on April 14, 2025. Each option

      4/15/25 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    SEC Filings

    See more
    • Amendment: SEC Form S-3/A filed by Cardiff Oncology Inc.

      S-3/A - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:13:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:10:08 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cardiff Oncology Inc.

      10-Q - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/8/25 4:00:18 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Leadership Updates

    Live Leadership Updates

    See more

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

      First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

      5/4/23 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

      Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

      2/2/23 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

      SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

      1/11/22 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/6/24 4:01:34 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/14/23 12:47:09 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cardiff Oncology Inc.

      SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

      1/26/23 1:30:22 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/18/24 4:37:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/16/24 5:00:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/12/24 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Kabbinavar Fairooz

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:06:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Levine James E.

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Smeal Tod

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      3/13/25 4:03:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care